BTIG Reiterates Buy on Mereo BioPharma Group, Maintains $1 Price Target
Mereo BioPharma Reports Third Quarter 2026 Financial Results
Mereo BioPharma Group Q3 EPS $(0.01), Inline, Sales $800.000K
JP Morgan Downgrades Mereo BioPharma Group to Underweight
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Mereo BioPharma Group Q2 EPS $(0.01), Inline
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Mereo BioPharma Group Q1 EPS $(0.01), Inline
European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading
European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading
We're Hopeful That Mereo BioPharma Group (NASDAQ:MREO) Will Use Its Cash Wisely
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
Mereo BioPharma Group Q4 EPS $(0.01), Inline
European Equities Traded in the US as American Depositary Receipts Little Changed in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
Mereo BioPharma Group (MREO) Is Up 74.4% After Mixed Setrusumab Phase 3 Data and Cash Update – Has The Bull Case Changed?
A Look At Mereo BioPharma (MREO) Valuation After Mixed Setrusumab Phase 3 Update And Conference Spotlight
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.